Researchers at Washington University School of Medicine in St. Louis have created a massive online database that matches thousands of genes linked to cancer and other diseases with drugs that target those genes. Some of the drugs are approved by the U.S. Food and Drug Administration, while others are in clinical trials or just entering the drug development pipeline.
A team led by scientists at The Scripps Research Institute has identified key signaling proteins in the inflammation process that contribute to the development of inflammatory diseases such as rheumatoid arthritis, psoriasis, sepsis and inflammatory bowel diseases.
Using the Food and Drug Administration's Adverse Event Reporting System (FAERS), a hospital electronic health records database, and an animal model, a team of researchers at the Icahn School of Medicine at Mount Sinai report that by adding a second drug to the diabetes drug rosiglitazone, adverse events dropped enormously. That suggests that drugs could be repurposed to improve drug safety, including lowering the risk of heart attacks.
Physician, scientist and specialty pharmaceuticals entrepreneur, Dr. Seth Lederman, can comment on the process of drug reformulation, development, and why investors should look for companies pursuing a 505(b)(2) FDA approval pathway.
Two gene alterations pair up to promote the growth of leukemia cells and their escape from anti-cancer drugs.
SUNY Downstate Medical Center's Sheryl Smith, PhD, has published new findings demonstrating a reproducible pathology that may help shed light on anxiety and mood volatility in methamphetamine dependence.
An Indiana University cancer researcher and his colleagues have discovered new therapeutic targets and drugs for certain types of leukemia or blood cancer.
Scientists from the Florida campus of The Scripps Research Institute have identified a new drug candidate for an inherited form of cancer with no known cure.
The discovery of genetic differences affecting up to a third of the population could take the guesswork out of prescribing the correct dose of 25 percent of drugs currently on the market, researchers say.
You may be able to eat all of the ice cream you want after having your tonsils removed, but researchers at Henry Ford Hospital in Detroit say you don’t necessarily need a prescription to reduce post-operative pain – an over-the-counter pain-reliever is just as effective.
A review of dozens of studies on the use of statin medications to prevent heart attacks shows that the commonly prescribed drugs pose no threat to short-term memory, and that they may even protect against dementia when taken for more than one year. The Johns Hopkins researchers who conducted the systematic review say the results should offer more clarity and reassurance to patients and the doctors who prescribe the statin medications.
Early treatment of heart attack patients with an inexpensive beta-blocker drug called metoprolol, while in transit to the hospital, can significantly reduce damage to the heart during a myocardial infarction, according to clinical trial study results published Oct. 1 in the journal Circulation.
A team led by scientists at The Scripps Research Institute has created the first comprehensive roadmap of the protein interactions that enable cells in the pancreas to produce, store and secrete the hormone insulin.
Highlighting an important but unexplored area of evolution, scientists at The Scripps Research Institute (TSRI) have found evidence that, over hundreds of millions of years, an essential protein has evolved chiefly by changing how it moves, rather than by changing its basic molecular structure. The work has implications not only for the understanding of protein evolution, but also for the design of antibiotics and other drugs that target the protein in question.
A bioinformatics approach to repurposing drugs resulted in identification of a class of antidepressants as a potential new treatment for small-cell lung cancer (SCLC), according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.
The anti-fungal drug Ciclopirox causes HIV-infected cells to commit suicide by jamming up the cells’ powerhouse, the mitochondria, according to a study by researchers at Rutgers New Jersey Medical School. And unlike current anti-HIV drugs, Ciclopirox completely eradicates infectious HIV from cell cultures, with no rebound of virus when the drug is stopped.
Sulfasalazine, a drug commonly prescribed to reduce diarrhea in patients with inflammatory bowel disease, does not reduce diarrhea in patients receiving radiation therapy for cancers in the pelvic area a Mayo Clinic-led study has found. The study also found that the medication may be associated with a higher risk of diarrhea than a placebo when used during radiation therapy to the pelvis. The results were presented today at the American Society of Radiation Oncology’s (ASTRO’s) 55th Annual Meeting in Atlanta.
Adding the chemotherapy drug cisplatin to a treatment plan of radiation therapy (RT) and high-dose-rate brachytherapy (HDRB) for stage IIIB cervical cancer is beneficial, according to research presented today at the American Society for Radiation Oncology’s (ASTRO’s) 55th Annual Meeting. The study also indicated that the combined treatments produced acceptable levels of toxicity.
Sulfasalazine does not reduce diarrhea, according to research presented today at the American Society of Radiation Oncology’s (ASTRO’s) 55th Annual Meeting. The study also determined that the medication may be associated with a higher risk of diarrhea than placebo.
Researchers at Washington University School of Medicine in St. Louis and Imperial College London are the first to identify the site where the widely used anesthetic drug propofol binds to receptors in the brain to sedate patients during surgery.
KaloBios Pharmaceuticals, Inc. (Nasdaq:KBIO) today announced the publication of Phase 1 study results for KB001, a first generation, anti-Pseudomonas aeruginosa (Pa) type III secretion system (TTSS) antibody, for use in patients with cystic fibrosis (CF). Data from this initial single dose clinical study supports the continuation of KaloBios' ongoing Phase 2 study of KB001-A, a second generation, anti-TTSS antibody in CF patients with chronic Pa infections.
About half of smokers seeking treatment for smoking cessation have a history of depression. Compared with smokers who are not depressed, those who suffer from a major depressive disorder (MDD) have greater difficulty quitting.
A Kansas State University research team has found a breakthrough herbal medicine treatment for a common human fungal pathogen that lives in almost 80 percent of people. The team discovered a medicinal herb called Gymnema slyvestre is both nontoxic and blocks the virulence properties of a common fungus called Candida albicans.
Using large and frequent doses of the pain-killer codeine may actually produce heightened sensitivity to pain, without the same level of relief offered by morphine, according to new research from the University of Adelaide.
Novel discovery by scientists from NUS and UCLA enhances delivery and retention of leukemia drug, paving the way for nanodiamonds to be used for chemotherapeutics.
Johns Hopkins scientists have identified a molecular marker called “Mig 6” that appears to accurately predict longer survival -- up to two years -- among patients prescribed two of the most widely used drugs in a class of anticancer agents called EGFR inhibitors.
Some of this year's flu vaccine will protect against four strains of the virus. There will also be vaccines which protect against three strains of the virus as well. This is the first year the four strain flu vaccine is available.
A new published study in Journal of Cellular Physiology by a team led by Dr. Antonio Giordano and Dr. Gianfranco Bellipanni of Sbarro Institute for Cancer Research and Molecular Medicine and Temple University (Philadelphia, USA) adds a new prospective on the research on pain perception.
A new study — the first to apply a new screening technique to human platelets — netted a potential drug target for preventing dangerous blood clots in high-risk people.
A recent Institute of Medicine report indicates that 116-million Americans live with some form of chronic pain. Historically, chemists have developed drugs aimed at just one biological target. Two drugs used together may metabolize differently or present other issues. This new drug, named UMB 425 by the University of Maryland School of Pharmacy research team, affects two different opioid receptors, providing diminished tolerance.
A research consortium that includes UAB has shown that a new drug for vasculitis, a potentially life-threatening auto-immune disease which causes inflammation in blood vessels, is as effective as standard therapy over 18 months.
Ideas that Henry Ford taught a century ago about the advantages of continuous mass production are finding their way into the manufacture of one of the few remaining products still made batch-wise: the billions of tablets, capsules and other forms of medicine that people take each year. That was the topic of a keynote address here today at the 246th National Meeting & Exposition of the American Chemical Society, the world’s largest scientific society.
With the “Valley of Death” looming as an increasingly serious obstacle to introducing better ways of preventing, diagnosing and treating diseases, a noted scientist today described a new approach for moving promising drug compounds out of laboratories and into the hands of patients and physicians. He spoke at the 246th National Meeting & Exposition of the American Chemical Society, the world’s largest scientific society, being held here this week.
An ingredient in a medicinal tea brewed from tree bark by tribal healers on the South Pacific island of Samoa — studied by scientists over the last 25 years — is showing significant promise as a drug lead in the long-sought goal of eliminating the AIDS virus from its sanctuaries in the body and thus eradicating the disease, a scientist said here today.
How many breakthrough new drugs never reach patients because tests in clinical trials suggested a high risk of liver damage when the drug actually was quite safe? That question underpins major international research efforts to modernize tests for drug-induced liver injury, mentioned here today at the 246th National Meeting & Exposition of the American Chemical Society, the world’s largest scientific society.
An international study led by Dana-Farber scientists found that the oral targeted drugs pazopanib (Votrient) and sunitinib (Sutent), approved for metastatic kidney cancer worked equally well, but one proved superior in tolerability.
Prescribing of “atypical” antipsychotic medications to children and young adults with behavioral problems or mood disorders may put them at unnecessary risk for type 2 diabetes, a Vanderbilt University Medical Center study shows. Young people using medications like risperidone, quetiapine, aripiprazol and olanzapine led to a threefold increased risk of developing type 2 diabetes within the first year of taking the drug, according to the study published Aug. 21 in the journal JAMA Psychiatry.
The newly expanded role that pharmacists in Canada now have in helping manage the health of patients can benefit both patients and physicians, according to an article in CMAJ (Canadian Medical Association Journal).
A new population-based study has found that patients with glioblastoma who died in 2010, after the Food and Drug Administration (FDA) approval of bevacizumab, had lived significantly longer than patients who died of the disease in 2008, prior to the conditional approval of the drug for the treatment of the deadly brain cancer. Bevacizumab is used to treat patients with certain cancers whose cancer has spread. The study appears in the journal Cancer.
A study by Johns Hopkins researchers shows that a fifth of U.S. neurologists appear unaware of serious drug safety risks associated with various anti-epilepsy drugs, potentially jeopardizing the health of patients who could be just as effectively treated with safer alternative medications.
Typical combinations of anti-HIV medications do not appear to cause language delays in children who where exposed to HIV in the womb and whose mothers took the antiretroviral drugs during pregnancy.
Collaboration utilizes Sanford-Burnham drug discovery platform to find new therapeutic targets for treating complications of obesity and diabetes
Study: If the science behind a drug shows it to be rationally targeted at a cancer-causing genetic mutation, and if early clinical trials show the drug is safe and happens to be especially effective, should the drug be held to the same time-consuming and expensive testing standards of traditional chemotherapies? Or is the clinical trials process a relic from the time of earlier, highly toxic therapies?
Results from a clinical trial of eteplirsen, a drug designed to treat Duchenne muscular dystrophy, suggest that the therapy allows participants to walk farther than people treated with placebo and dramatically increases production of a protein vital to muscle growth and health. The study, led by a team in The Research Institute at Nationwide Children’s Hospital, is the first of its kind to show these results from an exon-skipping drug—a class of therapeutics that allows cells to skip over missing parts of the gene and produce protein naturally.
A new study reports that the small intestine uses more cells than scientists had realized to absorb microspheres large enough to contain therapeutic protein drugs, such as insulin. The finding in rats, published in the Proceedings of the National Academy of Sciences, is potentially good news for developing a means for oral delivery of such drugs.
When U.S. physicians prescribe antibiotics, more than 60 percent of the time they choose some of the strongest types of antibiotics, referred to as “broad spectrum,” which are capable of killing multiple kinds of bacteria, University of Utah researchers show in a new study.
In a study in mice, researchers at Duke Medicine identified a protein that is critical to temporomandibular joint disorder pain, and could be a promising target for developing treatments for the disorder.
Immune Tolerance Network researchers demonstrate rituximab is as effective as the standard treatment protocol in ANCA-associated vasculitis.
Bitterness presents a key obstacle to the acceptance and effectiveness of beneficial drugs by children worldwide. A new review addresses this critical problem by highlighting recent advances in the scientific understanding of bitter taste, with special attention to the sensory world of children.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right